This may be because hypomethylating agents can up‐regulate checkpoint genes such as PD‐1, PD‐L1, and PD‐L2 in AML patients, which in turn serve as targets for checkpoint blockade. This evidence concerns the gene CD274 and acute myeloid leukemia.